Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Where Will It End? Lilly’s US Price Concessions Increase 30% In 2016

Executive Summary

Eli Lilly recorded $7.69bn in rebates and discounts in the US in 2016 as pharmacy benefit managers demanded greater price concessions in crowded categories like diabetes.


Related Content

US Retail Drug Spending Growth Slows Substantially In 2016
Sanofi's Drug Pricing Pledge Ties Increases To National Health Expenditure
Lilly Shows Diabetes Dominance, But Will It Last?
Which Pharma Firm Increases US Prices The Most?
Janssen's Drug Pricing Report Emphasizes Value Of Rebates
Drug Pricing: PhRMA Report Aims To Shift Focus To Supply Chain
Price Rebates Will Continue As ‘Fact Of Life’ In Drug Contracting
Lilly’s Insulin Discounts Target High-Deductible Insurance Gaps
Pfizer’s Read Criticizes Rebates Amid Changing Market Dynamics
Value-Based Contracting Needs Federal Safe Harbors To Flourish, Lilly Says


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts